Genre
ReviewJournal
Date
2016-09-23Author
Carnevale, VRohacs, T
Permanent link to this record
http://hdl.handle.net/20.500.12613/5033
Metadata
Show full item recordDOI
10.3390/ph9030052Abstract
© 2016 by the authors; licensee MDPI, Basel, Switzerland. Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca2+ permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX). Many compounds have been developed that either activate or inhibit TRPV1, but none of them are in routine clinical practice. This review will discuss the rationale for antagonists and agonists of TRPV1 for pain relief and other conditions, and strategies to develop new, better drugs to target this ion channel, using the newly available high-resolution structures.Citation to related work
MDPI AGHas part
PharmaceuticalsADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/5015